Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

Sameer A. Parikh, Hagop M. Kantarjian, Mary Ann Richie, Jorge E. Cortes, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

KIT D816V mutation has been observed in more than 90 of patients with systemic mastocytosis (SM). This mutation constitutively activates the mammalian target of rapamycin (mTOR) signaling pathway. We tested the efficacy of everolimus (RAD001), a novel oral mTOR inhibitor, at a dose of 10mg daily in an open label, non-comparative Phase II trial for patients with SM. Ten patients were enrolled from April 2007 to October 2008. Median age was 55 years, four were males, seven had indolent and three aggressive SM, and six were previously treated with other agents. Median duration of therapy was 4 months (range 0.218). No objective responses were noted. Four patients had a short-lasting subjective improvement in symptoms for a median duration of 3 months (range 315). Grade 13 diarrhea, mucositis, and neutropenia were the most common adverse effects. No Grade 4 toxicity was noted. In conclusion, everolimus does not result in appreciable clinical activity in patients with SM.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalLeukemia and Lymphoma
Volume51
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Systemic Mastocytosis
Sirolimus
Mutation
Mucositis
Neutropenia
Diarrhea
Everolimus

Keywords

  • D816V mutation
  • KIT mutation
  • Mast cell disease
  • MTOR

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. / Parikh, Sameer A.; Kantarjian, Hagop M.; Richie, Mary Ann; Cortes, Jorge E.; Verstovsek, Srdan.

In: Leukemia and Lymphoma, Vol. 51, No. 2, 01.02.2010, p. 269-274.

Research output: Contribution to journalArticle

Parikh, Sameer A. ; Kantarjian, Hagop M. ; Richie, Mary Ann ; Cortes, Jorge E. ; Verstovsek, Srdan. / Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. In: Leukemia and Lymphoma. 2010 ; Vol. 51, No. 2. pp. 269-274.
@article{1521100655e949fd80e6e187c08f8784,
title = "Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis",
abstract = "KIT D816V mutation has been observed in more than 90 of patients with systemic mastocytosis (SM). This mutation constitutively activates the mammalian target of rapamycin (mTOR) signaling pathway. We tested the efficacy of everolimus (RAD001), a novel oral mTOR inhibitor, at a dose of 10mg daily in an open label, non-comparative Phase II trial for patients with SM. Ten patients were enrolled from April 2007 to October 2008. Median age was 55 years, four were males, seven had indolent and three aggressive SM, and six were previously treated with other agents. Median duration of therapy was 4 months (range 0.218). No objective responses were noted. Four patients had a short-lasting subjective improvement in symptoms for a median duration of 3 months (range 315). Grade 13 diarrhea, mucositis, and neutropenia were the most common adverse effects. No Grade 4 toxicity was noted. In conclusion, everolimus does not result in appreciable clinical activity in patients with SM.",
keywords = "D816V mutation, KIT mutation, Mast cell disease, MTOR",
author = "Parikh, {Sameer A.} and Kantarjian, {Hagop M.} and Richie, {Mary Ann} and Cortes, {Jorge E.} and Srdan Verstovsek",
year = "2010",
month = "2",
day = "1",
doi = "10.3109/10428190903486220",
language = "English (US)",
volume = "51",
pages = "269--274",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

AU - Parikh, Sameer A.

AU - Kantarjian, Hagop M.

AU - Richie, Mary Ann

AU - Cortes, Jorge E.

AU - Verstovsek, Srdan

PY - 2010/2/1

Y1 - 2010/2/1

N2 - KIT D816V mutation has been observed in more than 90 of patients with systemic mastocytosis (SM). This mutation constitutively activates the mammalian target of rapamycin (mTOR) signaling pathway. We tested the efficacy of everolimus (RAD001), a novel oral mTOR inhibitor, at a dose of 10mg daily in an open label, non-comparative Phase II trial for patients with SM. Ten patients were enrolled from April 2007 to October 2008. Median age was 55 years, four were males, seven had indolent and three aggressive SM, and six were previously treated with other agents. Median duration of therapy was 4 months (range 0.218). No objective responses were noted. Four patients had a short-lasting subjective improvement in symptoms for a median duration of 3 months (range 315). Grade 13 diarrhea, mucositis, and neutropenia were the most common adverse effects. No Grade 4 toxicity was noted. In conclusion, everolimus does not result in appreciable clinical activity in patients with SM.

AB - KIT D816V mutation has been observed in more than 90 of patients with systemic mastocytosis (SM). This mutation constitutively activates the mammalian target of rapamycin (mTOR) signaling pathway. We tested the efficacy of everolimus (RAD001), a novel oral mTOR inhibitor, at a dose of 10mg daily in an open label, non-comparative Phase II trial for patients with SM. Ten patients were enrolled from April 2007 to October 2008. Median age was 55 years, four were males, seven had indolent and three aggressive SM, and six were previously treated with other agents. Median duration of therapy was 4 months (range 0.218). No objective responses were noted. Four patients had a short-lasting subjective improvement in symptoms for a median duration of 3 months (range 315). Grade 13 diarrhea, mucositis, and neutropenia were the most common adverse effects. No Grade 4 toxicity was noted. In conclusion, everolimus does not result in appreciable clinical activity in patients with SM.

KW - D816V mutation

KW - KIT mutation

KW - Mast cell disease

KW - MTOR

UR - http://www.scopus.com/inward/record.url?scp=76349119028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349119028&partnerID=8YFLogxK

U2 - 10.3109/10428190903486220

DO - 10.3109/10428190903486220

M3 - Article

C2 - 20038218

AN - SCOPUS:76349119028

VL - 51

SP - 269

EP - 274

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -